Abstract
Sunitinib, a first-line (1L) treatment option for patients with metastatic renal cell carcinoma (mRCC), has a standard dosing schedule of 50mg once daily for a 4-week on 2 weeks off cycle (4:2). However, studies with small selected populations have reported improved outcomes with schedule alterations. We investigated the impact of different 1L sunitinib dosing schedules on treatment duration and survival in a real-world setting for a nationwide Swedish mRCC cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
